CT52923 - ≥98% , CAS No.205256-55-9

CAS: 205256-55-9 Cat. No.: C650187 Formule: C23H25N5O4S Poids moléculaire: 467.54
DISPONIBLE À COMMANDE
QUALITÉ & PURETÉ ≥98%
Storage
Protected from light,Store at -80°C
Shipped In
Dry ice packs + Cold packs
★
Taille
Allemagne (EU)
USA*
Prix
Qté
5mg
C650187-5mg
Sur commande · 8–12 semaines
156,97€
10mg
C650187-10mg
Sur commande · 8–12 semaines
243,75€
25mg
C650187-25mg
Sur commande · 8–12 semaines
486,71€
50mg
C650187-50mg
Sur commande · 8–12 semaines
781,75€
100mg
C650187-100mg
Sur commande · 8–12 semaines
1 180,91€
Enter a quantity for the sizes you want to add.

Vue d’ensemble

CT52923 is a selective, orally active platelet-derived growth factor receptor (PDGFR) antagonist. CT52923 also is an ATP-competitive inhibitor. CT52923 can be used for the research variety of pathological diseases, including atherosclerosis, glomerulonephritis, liver cirrhosis, pulmonary fibrosis, and cancer.

In Vitro

CT52923 inhibit the PDGFRs and stem cell factor receptor with an IC 50 value of 100 to 200 nM. CT52923 (0.01-30 μM; 24 h) blocks plateletderived growth factor-induced smooth muscle cell migration or fibroblast proliferation with an IC 50 of 64 and 280 nM, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Migration AssayCell Line: Rat A10 smooth muscle cells Concentration: 0.01-30 μM Incubation Time: 24 h Result: Inhibited PDGF-induced cell migration with an IC 50 of 64 nM.

In Vivo

CT52923 (oral; 5, 15, 30, and 50 mg/kg; twice daily) can significantly inhibit neointima formation following carotid artery injury by oral administration in the rat . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Rat carotid artery balloon angioplasty model . Dosage: 5, 15, 30, and 50 mg/kg Administration: Oral gavage; twice daily Result: Inhibited PDGF-mediated response to vascular injury.

Form:Solid

Spécifications

Spécifications et pureté
≥98%
Mécanismes biochimiques et physiologiques
CT52923 is a selective, orally active platelet-derived growth factor receptor (PDGFR) antagonist. CT52923 also is an ATP-competitive inhibitor. CT52923 can be used for the research variety of pathological diseases, including atherosclerosis, glomeruloneph
Conditions de stockage de stockage
Protected from light,Store at -80°C
Expédié en
Dry ice packs + Cold packs
Ce produit nécessite l'expédition en chaîne froide. Les services terrestres et autres services économiques ne sont pas disponibles.
Type d'action
ANTAGONIST
Pureté
≥98%
Noms et identifiants
Poids moléculaire
467.54

Données avancées

Certificats (CoA, COO, BSE/TSE et tableau d'analyse)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Calculateurs de solution
Avis

Avis des clients

Souhaitez-vous que nous vous envoyions un message lorsque des réductions seront disponibles?

Me rappeler plus tard

Merci ! Veuillez vérifier votre boîte de réception e-mail pour confirmer.

Oups ! Les notifications sont désactivées.